|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 216.32 USD | -0.82% |
|
-2.62% | +1.44% |
| 02-12 | BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial | RE |
| 02-12 | Ascendis Pharma Shows Steady Progress Toward Long-Term Growth, Wedbush Says | MT |
| Capitalization | 11.19B 13.26B 10.21B 9.73B 18.08B 1,204B 18.75B 119B 47.14B 580B 49.74B 48.72B 2,036B | P/E ratio 2026 * |
39.1x | P/E ratio 2027 * | 16.6x |
|---|---|---|---|---|---|
| Enterprise value | 10.58B 12.54B 9.65B 9.2B 17.09B 1,139B 17.73B 112B 44.57B 548B 47.03B 46.06B 1,925B | EV / Sales 2026 * |
7.56x | EV / Sales 2027 * | 5x |
| Free-Float |
97.58% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ascendis Pharma A/S
| 1 day | -0.82% | ||
| 1 week | -2.62% | ||
| Current month | -4.33% | ||
| 1 month | +0.60% | ||
| 3 months | +5.83% | ||
| 6 months | +9.08% | ||
| Current year | +1.44% |
| 1 week | 211 |  | 225.19 |
| 1 month | 200.68 | | 242 |
| Current year | 188.08 | | 242 |
| 1 year | 124.06 | | 242 |
| 3 years | 64.33 | | 242 |
| 5 years | 61.58 | | 242 |
| 10 years | 11.92 | | 242 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
CEO | Chief Executive Officer | 67 | 30/11/2007 |
Scott Smith
DFI | Director of Finance/CFO | 53 | 07/08/2016 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 53 | 30/04/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
BRD | Director/Board Member | 67 | 30/11/2007 |
Albert Cha
CHM | Chairman | 54 | 27/05/2021 |
Lisa Bright
BRD | Director/Board Member | 59 | 31/03/2017 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.82% | -2.62% | +50.14% | +93.14% | 13.28B | |
| +1.19% | +2.21% | -12.40% | -5.01% | 47.61B | |
| -0.10% | -2.22% | +49.90% | +44.95% | 38.3B | |
| -0.21% | +8.18% | +36.90% | +65.96% | 36.11B | |
| -1.13% | -10.96% | -13.70% | -26.47% | 28.31B | |
| -1.05% | -1.21% | +136.81% | +277.09% | 18.62B | |
| +7.58% | +14.65% | +31,531.21% | +4,130.93% | 15.44B | |
| -1.37% | -3.96% | +30.06% | -5.14% | 13.71B | |
| -1.44% | -6.82% | +159.66% | +108.92% | 13.06B | |
| +2.88% | -21.03% | +25.83% | +105.78% | 12.15B | |
| Average | +0.48% | -2.97% | +3,199.44% | +479.02% | 23.66B | |
| Weighted average by Cap. | +0.27% | -1.95% | +2,092.64% | +320.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.4B 1.66B 1.28B 1.22B 2.26B 151B 2.35B 14.84B 5.9B 72.53B 6.22B 6.1B 255B | 1.99B 2.36B 1.81B 1.73B 3.21B 214B 3.33B 21.07B 8.37B 103B 8.84B 8.65B 362B |
| Net income | 285M 338M 260M 248M 460M 30.65B 477M 3.02B 1.2B 14.76B 1.27B 1.24B 51.81B | 691M 819M 630M 601M 1.12B 74.36B 1.16B 7.32B 2.91B 35.8B 3.07B 3.01B 126B |
| Net Debt | -610M -723M -556M -530M -985M -65.61B -1.02B -6.46B -2.57B -31.58B -2.71B -2.65B -111B | -1.25B -1.48B -1.14B -1.09B -2.02B -135B -2.1B -13.27B -5.28B -64.88B -5.57B -5.45B -228B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/02/26 | 216.32 $ | -0.82% | 698,795 |
| 12/02/26 | 218.10 $ | -1.53% | 1,684,412 |
| 11/02/26 | 221.49 $ | -1.20% | 962,607 |
| 10/02/26 | 224.19 $ | +0.97% | 967,204 |
| 09/02/26 | 222.03 $ | -0.05% | 670,322 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ASND Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition